Adults hospitalized with COVID-19 who also had kidney or liver disease had a lower risk of dying within 28 days if they received the antiviral remdesivir early, according to a large analysis of U.S. medical claims data published this week in Clinical Infectious Diseases.
The reduction was about 25 percent in patients with kidney disease and about 24 percent in patients with liver disease, compared with matched patients who did not receive the drug. Researchers from the University of Illinois and from Gilead Sciences, which manufactures remdesivir, conducted the study together.
